Articles From: Aventura Equities Announces Expanded Corporate Direction and Opportunities to AVEO Reports Third Quarter 2013 Financial Results


2014/2/13
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1089986&ProfileId=051205&sourceType=1 GEORGETOWN, SC --
Sign-up for Aventura Equities Announces Expanded Corporate Direction and Opportunities investment picks
2014/2/26
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1093389&ProfileId=051205&sourceType=1 GEORGETOWN, SC --
Sign-up for Aventura Equities Signs Definitive Agreement to Acquire Medical Marijuana Research Company investment picks
2014/3/14
NEW YORK , March 14, 2014 /PRNewswire/ -- The board of trustees (the " Board ") of the Avenue Income Credit Strategies Fund (NYSE: ACP) (the " Fund ") today announced that the annual meeting of shareholders of the Fund will be held on May 15, 2014 at 8:00 a.m., Eastern time , at the offices of Dechert LLP located at 1095 Avenue of the Americas, New York, New York .
Sign-up for Avenue Income Credit Strategies Fund Announces Annual Shareholder Meeting investment picks
2014/2/3
NEW YORK , Feb.
Sign-up for Avenue Income Credit Strategies Fund April Monthly Dividend investment picks
2013/8/1
NEW YORK , Aug.
Sign-up for Avenue Income Credit Strategies Fund August Monthly Dividend investment picks
2013/12/2
NEW YORK , Dec.
Sign-up for Avenue Income Credit Strategies Fund December Monthly Dividend investment picks
2014/2/3
NEW YORK , Feb.
Sign-up for Avenue Income Credit Strategies Fund February Monthly Dividend investment picks
2014/2/3
NEW YORK , Feb.
Sign-up for Avenue Income Credit Strategies Fund March Monthly Dividend investment picks
2013/11/1
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund November Monthly Dividend investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund November Monthly Dividend - Revised investment picks
NEW YORK , Aug.
Sign-up for Avenue Income Credit Strategies Fund October Monthly Dividend investment picks
NEW YORK , Sept.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
2013/9/25
NEW YORK , Sept.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
2013/10/22
NEW YORK , Oct.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
NEW YORK , Dec.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
2014/2/3
NEW YORK , Feb.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
NEW YORK , Aug.
Sign-up for Avenue Income Credit Strategies Fund September Monthly Dividend investment picks
2014/1/30
AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON ( B iomarker  A ssessment of  T ivozanib in  ON cology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.
Sign-up for AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer investment picks
2014/2/14
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozanib.
Sign-up for AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib investment picks
2014/4/10
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix ® companion diagnostic test.
Sign-up for AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC investment picks
2014/3/4
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.
Sign-up for AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014 investment picks
2014/3/13
AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance.
Sign-up for AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan investment picks
2013/8/9
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.m. (ET) in Boston.
Sign-up for AVEO Oncology to Present at the Canaccord Genuity 33rd Annual Growth Conference investment picks
2013/9/4
AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City.
Sign-up for AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference investment picks
2013/12/13
AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON ( B iomarker  A ssessment of  T ivozanib in  ON cology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
Sign-up for AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer investment picks
2014/3/20
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Sign-up for AVEO Regains Worldwide Rights to AV-203 investment picks
AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results.
Sign-up for AVEO Reports Second Quarter 2013 Financial Results investment picks
2013/11/7
AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.
Sign-up for AVEO Reports Third Quarter 2013 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Aventura Equities Announces Expanded Corporate Direction and Opportunities to AVEO Reports Third Quarter 2013 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity